Market News / Story
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiat…
ACCESS Newswire ·
ACCESS Newswire reports: Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹ Medical countermeasures need to scale along with that infrastructure Valion is developing an oral mucosal formulation of Entolimod that could potentially provide a needle-free administration option for acute radiation syndrome ("ARS") SAN ANTONIO, TX / ACCESS Newswire / October 9, 2026 / As nuclear power…
Related stories
ECB’s September minutes reveal full support for 25bp rate hikeRead story summary
By the time the ECB met in September, a 25bp rate hike had already come to be seen as the most likely outcome. The just-released minutes of that meeting show that the ECB’s Governing Council was united in its view that a worsening inflation outlook and economic resilience called for a hike. The minutes, however, give a less hawkish picture than ECB ...
VIEW SOURCE
Japan's Takaichi Rules Out Need for Reflationary Measures, Affirms BOJ IndependenceRead story summary
Japans Takaichi Rules Out Need for Reflationary Measures, Affirms BOJ Independence Japans Takaichi Seeks Market Trust Through Open and Transparent Communication
VIEW SOURCE- Fed minutes could detail rate-hike decision, policy path
Read story summary
A readout on Wednesday of the Federal Reserve's last policy meeting is expected to show a much broader debate than reflected in the unanimous decision to raise interest rates, with possible implications for the US central bank's next policy steps. The rate hike delivered after the end of the September 15-16 meeting was billed by Fed Chairman Kevin Warsh as ...
VIEW SOURCE